What Americans Aren’t Told About Psychiatric Medications | Robert Whitaker

32 snips

Dec 17, 2025

Robert Whitaker, an investigative journalist and author known for his work on psychiatric treatment, challenges the long-held belief that psychiatric drugs fix chemical imbalances in the brain. He reveals how this myth helped expand the pharmaceutical industry despite a lack of supporting evidence. Whitaker discusses alarming findings on long-term outcomes for schizophrenia and the potential harm of psychiatric medications, which can lead to chronic symptoms. He advocates for alternative approaches like Finland's Open Dialogue, suggesting a shift in how mental health is treated.

Ask episode

AI Snips

Chapters

Books

Transcript

Episode notes

ANECDOTE

Reporter Turned Skeptic After Research Discoveries

Robert Whitaker describes shifting from believing the chemical imbalance narrative to questioning it while reporting.
He recounts finding long-term studies and WHO data that contradicted the optimistic progress story.

INSIGHT

Better Outcomes Where Drugs Used Less

World Health Organization studies found better schizophrenia outcomes in developing countries where long-term antipsychotic use was uncommon.
Whitaker highlights this cross-cultural data as evidence that chronic drug regimes may worsen long-term outcomes.

ANECDOTE

Soteria Project Undermined The Drug Narrative

Whitaker recounts Loren Mosher's Soteria house studies which used selective, minimal medication and achieved good outcomes.
Mosher was fired after his findings challenged the psychiatric establishment's drug-centered narrative.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

For the past half century, Americans have been told that psychiatric drugs fix chemical imbalances in the brain. But this is nothing but a myth, says journalist Robert Whitaker.

Whitaker is the publisher of MadInAmerica.com and is known for his influential critiques of modern psychiatry and psychiatric drug treatment.

It was hypothesized that depression was due to too little serotonin and that schizophrenia was caused by too much dopamine—and that drugs could fix that, just like insulin for diabetes. But that was never backed up by evidence, Whitaker said.

“That was the story that was used to sell a whole second generation of psychiatric drugs and dramatically expand the psychiatric enterprise worldwide,” he said.

In 1999, Whitaker co-wrote a series of articles for the Boston Globe on psychiatric research and became a finalist for the 1999 Pulitzer Prize for Public Service, thereby establishing his reputation in this field. Later, he served as director of publications at Harvard Medical School.

“We have this story that we’re making great progress in diagnosing and treating mental disorders,” he told me.

U.S. spending on treating mental disorders has risen substantially over the past decades, from tens of billions in the late 1980s to more than $100 billion per year today. But there is no evidence, he says, that these drugs improve long-term outcomes. On the contrary, there is plenty of evidence that psychiatric drugs can actually make things worse, he says.

“They actually cause chemical imbalances, increase the chronicity of disorders, increase functional impairment, and you see rising disability rates wherever you see this paradigm of care adopted,” he says.

Certain antipsychotics for schizophrenia, for instance, can actually reduce brain tissue, particularly in the first year, and that’s been associated with cognitive decline and a worsening of symptoms.

Evidence shows that other countries, including developing nations, that have not adopted this same approach have seen much better outcomes, he says.

In this episode, he breaks down his findings from decades of studying this issue. Whitaker is the author of “Mad in America” and “Anatomy of an Epidemic.”

Views expressed in this video are opinions of the host and the guest, and do not necessarily reflect the views of The Epoch Times.